Bluebird bio placed the company’s Phase I/II and Phase III trials of LentiGlobin gene therapy for sickle cell disease (SCD) on temporary suspension.

Researchers at the Karolinska Institute in Sweden evaluated more than 33,000 compounds on SAMHD1 to determine which ones could inhibit the effects of the enzyme on cytarabine, one of the most-used drugs for acute myeloid leukemia (AML).

The European Commission approved Astellas Pharma’s oral once-daily therapy Xospata as a monotherapy for treating adults with relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Celgene Corporation announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study QUAZAR AML-001.

Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Tibsovo (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Trovagene Inc., a precision medicine biotechnology company, announced that the U.S. Food and Drug Administration granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML).

The U.S. FDA approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders.